Novel Co-Stimulatory Factors
More efficacious CAR-T cells with novel co-stimulatory factors while producing less cytokines.
Co-stimulatory factors impart different functional, metabolic, and safety profiles upon the CAR-T cells. The best studied CAR-T cells are second-generation CAR-Ts, which have CD28 or 4-1BB co-stimulatory domains. These CAR designs have been used in clinical for treat relapsed and/or refractory B cell malignancies, the products of which have been approved by FDA in 2017. Cytokines release syndrome (CRS) and neurotoxicity after CAR-T infusion are the major causes of deaths. Based on discovery research. Our CAR-T cells with novel co-stimulatory factors appear more efficacious while producing less cytokines.